|
|
Other links at Articles > Diabetes and Endocrinology |
| 1. |
FDA Safety Changes: DDAVP and Januvia
|
|
|
The FDA has approved revisions to the safety labeling for desmopressin acetate nasal spray, injection, rhinal tube, and tablets (DDAVP), and sitagliptin phosphate tablets (Januvia). Medscape Medical News
|
| 2. |
More Bone Formation, Less Resorption With Infliximab for RA
|
|
|
There is an improvement in the formation of bone and a reduction in bone resorption markers with the use of the anti-tumor necrosis factor-alpha (anti-TNF-alpha) drug infliximab in patients with rheumatoid arthritis (RA) whose disease has not responded to standard therapy. Reuters Health Information
|
|
|